充血性心力衰竭 - The Left Main and Coronary Artery Bifurcation Lesion Summit (CBS)

中文

Home

AT CBS

•　General Information •　Welcome Message •　Association and Affiliations •　Contact Us

Faculty

•　Course Directors •　Director of Consultative Commi •　Director of Academic Committee •　Members of Academic Committee •　General Secretary •　International Faculty •　Hong Kong and Taiwan Faculty •　Domestic Faculty

Program

•　Program at a Glance •　Program Search

Events

•　Slides •　Photos •　Interviews •　Videos

Scientific Library

•　Abstract

•　Acute Myocardial Infarction

•　Bifurcation Stenting

•　Cardio-oncology

•　Congestive Heart Failure

•　DAPT Duration

•　Drug Coated Balloon

•　Fractional Flow Reserve

•　IVUS Guidance

•　Optical Coherence Tomography

•　Pulmonary Hypertension

•　Rotational Atherectomy

•　Shear Stress

•　Stenting Left Main

•　Recommeded Article •　Top 10 Literature

Registration

•　Registration Information •　Faculty Registration •　International Registration

History

•　CBS2016 •　CBS2015 •　CBS2014 •　CBS2013 •　CBS2012

Home < 科学研究 < 文章摘要 < 充血性心力衰竭 <

充血性心力衰竭

Abstract

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Lifestyle Modifications for Preventing and Treating Heart Failure
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation
When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5)
H2FPEF Score for Predicting Future Heart Failure in Stable Outpatients With Cardiovascular Risk Factors
SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL
Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes

|<<... 9 10 11 12 13 14 15 ...>>|

Editorial

JOURNAL：Circulation.

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF

Martinez FA, Serenelli M, Nicolau JC et al.

Keywords: dapagliflozin; HFrEF; efficacy; safety

FULL TEXT PDF